ATE511654T1 - Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern - Google Patents
Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpernInfo
- Publication number
- ATE511654T1 ATE511654T1 AT03773780T AT03773780T ATE511654T1 AT E511654 T1 ATE511654 T1 AT E511654T1 AT 03773780 T AT03773780 T AT 03773780T AT 03773780 T AT03773780 T AT 03773780T AT E511654 T1 ATE511654 T1 AT E511654T1
- Authority
- AT
- Austria
- Prior art keywords
- low
- antibodies
- mab
- recruited
- antigens
- Prior art date
Links
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 abstract 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000033581 fucosylation Effects 0.000 abstract 1
- 150000004676 glycans Chemical group 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000590 parasiticidal effect Effects 0.000 abstract 1
- 239000002297 parasiticide Substances 0.000 abstract 1
- 230000018491 positive regulation of cytokine secretion Effects 0.000 abstract 1
- 238000006884 silylation reaction Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0211415A FR2844520B1 (fr) | 2002-09-13 | 2002-09-13 | Utilisation d'un anticorps induisant la secretion de cytokines en therapie |
| FR0211416A FR2844521B1 (fr) | 2002-09-13 | 2002-09-13 | Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices |
| PCT/FR2003/002715 WO2004024768A2 (fr) | 2002-09-13 | 2003-09-15 | Anticorps induisant la production de cytokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE511654T1 true ATE511654T1 (de) | 2011-06-15 |
Family
ID=31995630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03773780T ATE511654T1 (de) | 2002-09-13 | 2003-09-15 | Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7595165B2 (de) |
| EP (2) | EP1537419B1 (de) |
| JP (1) | JP4368800B2 (de) |
| AT (1) | ATE511654T1 (de) |
| AU (1) | AU2003282161B2 (de) |
| CA (1) | CA2498315C (de) |
| DK (1) | DK1537419T3 (de) |
| IL (1) | IL167385A (de) |
| WO (1) | WO2004024768A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511654T1 (de) * | 2002-09-13 | 2011-06-15 | Lfb Biotechnologies | Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| FR2895086B1 (fr) * | 2005-12-16 | 2012-10-05 | Lab Francais Du Fractionnement | Potentialisation de l'apoptose par des anticorps monoclonaux |
| ATE501436T1 (de) * | 2006-09-13 | 2011-03-15 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| FR2968561B1 (fr) † | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
| FR3064007A1 (fr) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
| KR20210138592A (ko) * | 2019-02-14 | 2021-11-19 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 면역 세포 효력을 검정하기 위한 자극제의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4070500A (en) * | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
| FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| ATE511654T1 (de) * | 2002-09-13 | 2011-06-15 | Lfb Biotechnologies | Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern |
-
2003
- 2003-09-15 AT AT03773780T patent/ATE511654T1/de active
- 2003-09-15 WO PCT/FR2003/002715 patent/WO2004024768A2/fr not_active Ceased
- 2003-09-15 AU AU2003282161A patent/AU2003282161B2/en not_active Ceased
- 2003-09-15 EP EP03773780A patent/EP1537419B1/de not_active Expired - Lifetime
- 2003-09-15 CA CA2498315A patent/CA2498315C/fr not_active Expired - Fee Related
- 2003-09-15 EP EP09152731A patent/EP2092939A3/de not_active Withdrawn
- 2003-09-15 JP JP2004535611A patent/JP4368800B2/ja not_active Expired - Fee Related
- 2003-09-15 US US10/527,665 patent/US7595165B2/en not_active Expired - Fee Related
- 2003-09-15 DK DK03773780.6T patent/DK1537419T3/da active
-
2005
- 2005-03-10 IL IL167385A patent/IL167385A/en active IP Right Grant
-
2009
- 2009-09-28 US US12/585,900 patent/US20100323368A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2498315C (fr) | 2013-01-29 |
| EP2092939A2 (de) | 2009-08-26 |
| WO2004024768A2 (fr) | 2004-03-25 |
| JP2006517087A (ja) | 2006-07-20 |
| AU2003282161A1 (en) | 2004-04-30 |
| EP1537419A2 (de) | 2005-06-08 |
| US7595165B2 (en) | 2009-09-29 |
| AU2003282161B2 (en) | 2010-06-24 |
| WO2004024768A3 (fr) | 2004-09-30 |
| DK1537419T3 (da) | 2011-06-27 |
| US20050249732A1 (en) | 2005-11-10 |
| CA2498315A1 (fr) | 2004-03-25 |
| EP2092939A3 (de) | 2011-12-21 |
| US20100323368A1 (en) | 2010-12-23 |
| EP1537419B1 (de) | 2011-06-01 |
| JP4368800B2 (ja) | 2009-11-18 |
| IL167385A (en) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191609T1 (hr) | Protein | |
| WO2004029092A8 (fr) | Anticorps pour adcc et induisant la production de cytokines. | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
| CR20130150A (es) | Proteínas de la unión a il-12/p40 (divisional exp. 9599) | |
| LTC2380910I2 (lt) | Antigeną surišančios molekulės su padidintu Fc receptoriaus prisirišimo gimingumu ir efektorine funkcija | |
| PH12021550041A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
| PL374587A1 (en) | Pharmaceutical compositions directed to erb-b1 receptors | |
| RU2008133032A (ru) | Антитела к ох-2/сd200 и их применение | |
| EA200601752A1 (ru) | Антимиостатиновые антитела | |
| NZ616992A (en) | Anti-ilt7 antibody | |
| CN116920085A (zh) | 抗-vista（b7h5）抗体 | |
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
| WO2003078600A3 (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
| FI973120A0 (fi) | Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa | |
| NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
| PE20030846A1 (es) | Anticuerpos para cd40 | |
| MX2022012182A (es) | Metodos de uso de anticuerpos anti-trem2. | |
| ATE488530T1 (de) | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel | |
| WO2006133450A3 (en) | Anti-cd19 antibody therapy for the transplantation | |
| RU2406730C2 (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| WO2004108766A3 (en) | Anti-hgf-r antibodies and their use | |
| ATE526409T1 (de) | Humanisierte antikörper spezifisch für sowohl cd45rb als auch cd45ro | |
| MXPA04003508A (es) | Anticuerpos humanos que se unen a mn. | |
| MY137078A (en) | Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors. | |
| TW200626614A (en) | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1537419 Country of ref document: EP |